만성 신장병(CKD) 시장 규모, 점유율 및 성장 분석 : 진단별, 치료법별, 투여 경로별, 최종 사용자별, 지역별 산업 예측(2025-2032년)

Global Chronic Kidney Disease Market size was valued at USD 14.1 billion in 2023 and is poised to grow from USD 16.93 billion in 2024 to USD 73.3 billion by 2032, growing at a CAGR of 20.1% during the forecast period (2025-2032).

The global chronic kidney disease (CKD) market is experiencing robust growth due to the increasing prevalence of diabetes and hypertension, which are key contributors to CKD. As the global population ages, the natural decline in kidney function exacerbates this issue. Growing awareness among patients and healthcare providers is fostering early identification and diagnosis of CKD, which in turn sustains high demand for therapeutic drugs, intervention strategies, and innovative technological treatments. This heightened recognition of CKD and the urgency for effective management solutions are key market drivers, ensuring continuous growth and expansion opportunities within the healthcare sector addressing this chronic condition.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Chronic Kidney Disease market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Chronic Kidney Disease Market Segments Analysis

Global Chronic Kidney Disease Market is segmented by Diagnosis, Treatment, Route of Administration, End User and region. Based on Diagnosis, the market is segmented into Blood Test, Urine Test, Imaging Test and Kidney Biopsy. Based on Treatment, the market is segmented into Drugs, Dialysis, Kidney Transplant, ACE Inhibitors, Blood Test and Other Treatments. Based on Route of Administration, the market is segmented into Oral, Intravenous and Subcutaneous. Based on End User, the market is segmented into Hospital and Clinics, Ambulatory Surgery Centers (ASCs), Dialysis Centers and Other End-Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Chronic Kidney Disease Market

The global market for chronic kidney disease is primarily driven by individuals suffering from diabetes and hypertension, the two leading contributors to kidney impairment. As the prevalence of these significant chronic conditions intensifies, the demand for treatment options will inevitably rise, correlating with an increased incidence of chronic kidney disease. This growing patient population highlights the urgent need for effective therapeutic interventions and management strategies, emphasizing the urgency for healthcare solutions that address the complexities of kidney health within the broader framework of chronic disease management. Consequently, this presents substantial opportunities for innovation and development within the market.

Restraints in the Global Chronic Kidney Disease Market

The management of advanced chronic kidney disease presents substantial financial challenges, as treatments such as dialysis and kidney transplants entail considerable expenses. This financial strain not only translates to a heavy burden for patients, particularly in regions with limited access to quality health insurance, but it also impacts the fiscal resources of national healthcare systems. The high costs associated with care can create barriers to accessing necessary treatments, leading to disparities in patient outcomes and placing additional stress on healthcare budgets. As a result, addressing these economic constraints is crucial for improving care and ensuring equitable access for all patients facing chronic kidney disease.

Market Trends of the Global Chronic Kidney Disease Market

The global chronic kidney disease market is witnessing a significant shift towards early diagnosis and proactive intervention strategies. This evolving trend emphasizes the importance of early detection and management, particularly for at-risk populations, rather than solely focusing on late-stage treatment. Healthcare systems worldwide are increasingly prioritizing preventive measures, fostering innovations in screening technologies and diagnostic tools. This movement aims to identify chronic kidney disease in its initial stages, ultimately driving the development of novel therapeutic agents designed to slow disease progression effectively. As a result, the market is poised for substantial growth, reflecting a holistic approach to kidney health management.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Chronic Kidney Disease Market Size by Diagnosis & CAGR (2025-2032)

• Market Overview
• Blood Test
  • Serum Creatinine Test
  • Glomerular Filtration Rate (GFR) Test
  • Blood Urea Nitrogen (BUN) Test
  • Electrolyte Tests
• Urine Test
  • Urinalysis
  • 24-hour Urine Collection
  • Urine Protein Test
  • Urine Albumin-To-Creatinine Ratio (ACR)
• Imaging Test
  • Ultrasound
  • CT Scan
  • MRI
  • X-ray
• Kidney Biopsy
  • Percutaneous Kidney Biopsy
  • Open Kidney Biopsy
  • Laparoscopic Kidney Biopsy

Global Chronic Kidney Disease Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Drugs
• Dialysis
• Kidney Transplant
• ACE Inhibitors
• Blood Test
• Other Treatments

Global Chronic Kidney Disease Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Intravenous
• Subcutaneous

Global Chronic Kidney Disease Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospital and Clinics
• Ambulatory Surgery Centers (ASCs)
• Dialysis Centers
• Other End-Users

Global Chronic Kidney Disease Market Size & CAGR (2025-2032)

• North America (Diagnosis, Treatment, Route of Administration, End User)
  • US
  • Canada
• Europe (Diagnosis, Treatment, Route of Administration, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Diagnosis, Treatment, Route of Administration, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Diagnosis, Treatment, Route of Administration, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Diagnosis, Treatment, Route of Administration, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AstraZeneca (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Medical Care (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DaVita Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (GSK) (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Travere Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vera Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ProKidney (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Akebia Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Calliditas Therapeutics AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (BD) (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Renalytix Plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations